This Center for Cancer Nanotechnology Excellence and Translation (CCNE-T) brings together scientists and physicians from Stanford University, University of California Berkeley/Lawrence Berkeley National Lab, University of California Los Angeles, University of Southern California and the Massachusetts Institute of Technology. The grant also leverages on several activities in cancer biomarker discovery/validation with the Canary Foundation and the Fred Hutchinson Cancer Center. This research proposal is centered around our vision that in vitro diagnostics used in conjunction with in vivo diagnostics can markedly impact future cancer patient management. Furthermore, we believe that nanotechnology can significantly advance both in vitro diagnostics through proteomic nanosensors and in vivo diagnostics through nanoparticles for molecular imaging. The cancer-related biochemical pathways targeted will be the Her kinase axis with a focus on predicting and monitoring response to lung cancer therapy. An additional focus will be on the earlier detection of Ovarian Cancer. We have assembled a highly interdisciplinary team of scientists from the fields of chemistry, materials science and engineering, molecular imaging, oncology, cancer biology, protein engineering, and mathematical modeling in order to accomplish our goals. We highly leverage resources at the Stanford Bio-X and Nanoscale Science and Engineering Programs, the California Nanosystems Institute, and the Cancer Centers of Stanford/UCL/VUSC/Fred Hutchinson. We will utilize significant resources at several small companies we have started and General Electric. We have direct links to a Fred Hutchinson Ovarian SPORE, a recently funded Physical Sciences Oncology Center (PSOC), the ICMIC P50, ICBP, and NTR at Stanford. Furthermore, the Canary Foundation will provide more than $3M towards clinical trials to translate our nanotechnologies and help with outreach. Four research projects and three cores are proposed. Project #1 focuses on novel smart nanoparticles including Raman and self-assembling nanoparticles, Project #2 focuses on the use of magneto-nanotechnology for blood proteomics and cell sorting. Project #3 focuses on the use of multiple nano-platforms to interrogate single circulating tumor cells. Project #4 focuses on molecular imaging of ovarian cancer with photoacoustics and Raman nanoparticles, and monitoring response to therapy using imaging and magneto-nanosensors. Core #1 will facilitate Nanoinformatics, Core #2 will provide resources for nanocharacterization and nanofabrication, Core #3 will facilitate clinical translation by linking our nanotechnologies to existing patient samples and ongoing as well as new clinical trials. With our highly interactive and cohesive program focused on developing and validating nanotechnology for anti-cancer therapy response and earlier cancer detection, we will imagine, invent, and innovate for the benefit of cancer patients.

Public Health Relevance

In the CCNE-T program, our multidisciplinary scientists and physician use nanotechnology to create the tiniest of devices (one billionth of a meter in size) that will enable us to eventually screen individuals by a simple blood test. By then performing an analysis and using imaging, we will be able to find problem cells and simultaneously eradicate or treat those cells successfully before they have grown out of control. Through use of today's advanced nanotechnology materials and molecular biology techniques for earlier detection and treatment monitoring, we expect to dramatically improve cancer survival rates and provide reassurance to patients that their treatment is effective.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center--Cooperative Agreements (U54)
Project #
5U54CA151459-05
Application #
8726310
Study Section
Special Emphasis Panel (ZCA1-GRB-S (M1))
Program Officer
Hartshorn, Christopher
Project Start
2010-08-26
Project End
2015-07-31
Budget Start
2014-08-01
Budget End
2015-07-31
Support Year
5
Fiscal Year
2014
Total Cost
$2,374,791
Indirect Cost
$746,215
Name
Stanford University
Department
Radiation-Diagnostic/Oncology
Type
Schools of Medicine
DUNS #
009214214
City
Stanford
State
CA
Country
United States
Zip Code
94305
Pu, Kanyi; Shuhendler, Adam J; Valta, Maija P et al. (2014) Phosphorylcholine-coated semiconducting polymer nanoparticles as rapid and efficient labeling agents for in vivo cell tracking. Adv Healthc Mater 3:1292-8
Hudak, Carolyn S; Gulyaeva, Olga; Wang, Yuhui et al. (2014) Pref-1 marks very early mesenchymal precursors required for adipose tissue development and expansion. Cell Rep 8:678-87
Cheng, Kai; Kothapalli, Sri-Rajasekhar; Liu, Hongguang et al. (2014) Construction and validation of nano gold tripods for molecular imaging of living subjects. J Am Chem Soc 136:3560-71
Zhang, Mingliang; Bechstein, Daniel J B; Wilson, Robert J et al. (2014) Wafer-scale synthesis of monodisperse synthetic magnetic multilayer nanorods. Nano Lett 14:333-8
Sinclair, Robert; Kempen, Paul Joseph; Chin, Richard et al. (2014) The Stanford Nanocharacterization Laboratory (SNL) and Recent Applications of an Aberration-Corrected Environmental Transmission Electron Microscope. Adv Eng Mater 16:476-481
Dimov, Ivan K; Lu, Rong; Lee, Eric P et al. (2014) Discriminating cellular heterogeneity using microwell-based RNA cytometry. Nat Commun 5:3451
Pu, Kanyi; Shuhendler, Adam J; Jokerst, Jesse V et al. (2014) Semiconducting polymer nanoparticles as photoacoustic molecular imaging probes in living mice. Nat Nanotechnol 9:233-9
Sasportas, Laura Sarah; Gambhir, Sanjiv Sam (2014) Imaging circulating tumor cells in freely moving awake small animals using a miniaturized intravital microscope. PLoS One 9:e86759
Park, Seung-Min; Sabour, Andrew F; Son, Jun Ho et al. (2014) Toward integrated molecular diagnostic system (i MDx): principles and applications. IEEE Trans Biomed Eng 61:1506-21
Wang, Jianbin; Quake, Stephen R (2014) RNA-guided endonuclease provides a therapeutic strategy to cure latent herpesviridae infection. Proc Natl Acad Sci U S A 111:13157-62

Showing the most recent 10 out of 57 publications